RNA-coupled CRISPR Screens Reveal ZNF207 as a Regulator of LMNA Aberrant Splicing in Progeria. Behera, Kim, Kordale et al.

Published: 25 November 2025| Version 1 | DOI: 10.17632/xvzfdm8kky.1
Contributors:
,
,
, Filip Pekovic, Arun Prasath Damodaran, Bandana Kumari, Sandra Vidak, Ethan Dickson, Mei-Sheng Xiao, Gerard Duncan, Thorkell Andresson, Tom Misteli, Eugene Valkov,

Description

Despite progress in understanding pre-mRNA splicing, the regulatory mechanisms controlling most alternative splicing events remain unclear. We developed CRASP-Seq, a method that integrates pooled CRISPR-based genetic perturbations with deep sequencing of splicing reporters, to quantitively assess the impact of all human genes on alternative splicing from a single RNA sample. CRASP-Seq identified both known and novel regulators, enriched for proteins involved in RNA splicing and metabolism. As proof-of-concept, CRASP-Seq analysis of an LMNA cryptic splicing event linked to progeria uncovered ZNF207, primarily known for mitotic spindle assembly, as a regulator of progerin splicing. ZNF207 depletion enhances canonical LMNA splicing and decreases progerin levels in patient-derived cells. We further show that ZNF207’s zinc finger domain broadly impacts alternative splicing through direct interactions with U1 snRNP components. These findings position ZNF207 as a U1 snRNP auxiliary factor and demonstrate the power of CRASP-Seq to uncover key regulators and domains of alternative splicing.

Files

Steps to reproduce

Please refer to the manuscript

Institutions

  • National Institutes of Health
  • National Cancer Institute
  • Center for Cancer Research

Categories

Electrophoretic Mobility-Shift Assay, Western Blot, Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis, Agarose Gel Electrophoresis

Licence